hotspot -WSS

hotspot

author：explore 2025-10-01 10:36:57 - browse：37

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： FDA clears Verve to begin U.S. study of gene

Wikipedia

WSS

Health tech investors get more selective as pandemic boom fades

Study: Spinal cord stimulation helps patients with paralysis walk again

PBMs are inflating the cost of generic drugs. They must be reined in

How the first Native Hawaiian psychiatrist helped diversify medicine

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Wikipedia

hotspot

leisure time

Cancer drug shortages should be causing more outrage

Health officials lay out plans to cope with respiratory virus season

Activists slam private health insurers over coverage restrictions

Why a market frenzy over new weight loss drugs defies logic

Trump demands the U.S. pay no more for drugs than other countries … again

Roivant's CEO is a star, but biotech's black hole persists

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Summit: Meghan O’Rourke on making chronic illness visible

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Former Pear Therapeutics executives start new VC firm

hotspot

Vivek Ramaswamy made waves in the debate, much as in biotech

Health tech investors get more selective as pandemic boom fades

Abortion policy in the spotlight at Republican debate

STAT Summit: Ending the crisis of Black deaths in the U.S.

National associations that represent hospice owe an apology

STAT Readout: Friday, Oct. 20 biotech updates

focus

knowledge

Wikipedia

knowledge